Skip to content
Inciteful Med

The Biological Switch: Understanding the Genetics of Noonan Syndrome

Last updated:

Noonan syndrome is a genetic condition caused by 'gain-of-function' mutations in the RAS/MAPK signaling pathway, most commonly involving the PTPN11 gene. About 60% of cases are new, spontaneous mutations, while the remaining cases are inherited from a parent.

Key Takeaways

  • • Noonan syndrome is caused by a genetic mutation that leaves the RAS/MAPK biological pathway stuck in an active or 'on' position.
  • • The condition is part of a family of genetic disorders known as RASopathies.
  • • A mutation in the PTPN11 gene is the most common cause, accounting for about half of all cases.
  • • Different genes are linked to specific features, such as RAF1 and RIT1 mutations being strongly associated with a thickened heart muscle.
  • • While it is an autosomal dominant condition, approximately 60% of cases are new (de novo) mutations rather than being inherited from a parent.

To understand Noonan syndrome, it helps to think of the body as having a series of biological “switches” that tell cells when to grow, divide, and develop. In Noonan syndrome, one of these switches is stuck in the “on” position [1][2].

The RAS/MAPK Pathway: The Body’s Signaling Highway

The specific group of switches involved is called the RAS/MAPK signaling pathway [2]. This is a vital communication network inside your cells that acts like a relay race. One protein passes a signal to the next, eventually reaching the center of the cell to give instructions for normal development [2][3].

Because Noonan syndrome is caused by a problem in this specific pathway, it belongs to a family of genetic conditions called RASopathies [4][5].

What is a “Gain-of-Function” Mutation?

In most people with Noonan syndrome, the genetic change is what scientists call a gain-of-function mutation [1][6].

  • Normal Function: Usually, the proteins in the RAS/MAPK pathway turn on when the body needs to grow and turn off when the job is done [2].
  • Gain-of-Function: The mutation causes a protein to become overactive or “hyperactive.” It stays turned on or is too easy to trigger, leading to the wide range of physical and developmental features seen in Noonan syndrome [1][7].

The Genes Involved

Several different genes can cause Noonan syndrome if they have a mutation. Each gene provides instructions for a different “runner” in the signaling relay race [8][9].

  • PTPN11 (50% of cases): The most common gene involved. It provides instructions for a protein called SHP-2, which helps regulate the pathway’s “on” switch [1][10].
  • SOS1: Helps activate the pathway; mutations here are often linked to specific skin or hair features [8][9].
  • RAF1 and RIT1: Mutations in these genes are more strongly associated with certain heart conditions, like a thickened heart muscle (hypertrophic cardiomyopathy) [11][12].
  • LZTR1: A unique gene that can be inherited in different ways and is sometimes linked to more severe heart issues [1][8].

How It Is Inherited

Noonan syndrome is an autosomal dominant condition [13]. This means a person only needs one copy of the mutated gene (from either parent) to have the syndrome. However, the way it starts can vary:

  • De Novo Mutations (approx. 60%): In more than half of cases, the mutation is “de novo,” meaning it happened for the first time in the child and was not inherited from either parent [14][15].
  • Inherited Cases: The remaining cases are inherited from a parent who also has Noonan syndrome [14]. Because symptoms can be very mild, some parents only discover they have the condition after their child is diagnosed [16].

If a person has Noonan syndrome, there is a 50% chance of passing the gene change to each of their children [13]. If a child has a de novo mutation, the risk of the parents having another child with the same condition is generally very low [13][15].

Return to Home Page

Frequently Asked Questions

Is Noonan syndrome inherited from a parent?
Noonan syndrome can be inherited from a parent, but in about 60% of cases, it is a new or 'de novo' mutation. This means the genetic change happened for the first time in the child and was not passed down from either parent.
What does a gain-of-function mutation mean in Noonan syndrome?
A gain-of-function mutation means a specific protein in the body's communication pathway becomes overactive. Instead of turning on and off normally, the biological switch stays stuck in the 'on' position, leading to the developmental features of the syndrome.
What is the most common gene that causes Noonan syndrome?
The most common gene involved is PTPN11, which accounts for about 50% of Noonan syndrome cases. This gene provides instructions for a protein called SHP-2 that helps regulate how cells grow and divide.
What are the chances of having another child with Noonan syndrome?
If a child has a new (de novo) mutation, the risk of parents having another child with the condition is generally very low. However, if a parent has Noonan syndrome, there is a 50% chance of passing the genetic change to each future child.
How do RAF1 and RIT1 gene mutations affect the heart?
Mutations in the RAF1 and RIT1 genes are more strongly associated with certain heart conditions. Specifically, they carry a higher risk for hypertrophic cardiomyopathy, which is a thickening of the heart muscle.

Questions for Your Doctor

  • • Which specific gene mutation was found, and is it a 'gain-of-function' variant?
  • • Does the gene mutation identified in our case (e.g., RAF1 or RIT1) carry a higher risk for specific heart conditions like hypertrophic cardiomyopathy?
  • • Was this mutation inherited from either parent, or is it a 'de novo' (new) mutation?
  • • What are the chances of this condition being passed on to future children or other family members?
  • • Can you explain how this specific genetic change is affecting my child's growth and development?

Questions for You

  • • Does knowing the specific genetic cause change how I feel about the diagnosis?
  • • How can I explain this 'biological switch' concept to other family members or teachers?
  • • What questions do I still have about how Noonan syndrome is inherited?
  • • Am I interested in connecting with a genetic counselor to discuss the results in more detail?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Refractory Chylothorax and Ventricular Hypertrophy Treated with Trametinib in a Patient with Noonan Syndrome: 18-Month Follow-Up.

    Pascarella A, Limongelli G, De Falco A, et al.

    Children (Basel, Switzerland) 2024; (11(11)) doi:10.3390/children11111342.

    PMID: 39594917
  2. 2

    Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.

    Song Y, Bi Z, Liu Y, et al.

    Genes & diseases 2023; (10(1)):76-88 doi:10.1016/j.gendis.2022.05.006.

    PMID: 37013062
  3. 3

    MEK inhibitors: a promising targeted therapy for cardiovascular disease.

    Mohammed KAK, Madeddu P, Avolio E

    Frontiers in cardiovascular medicine 2024; (11()):1404253 doi:10.3389/fcvm.2024.1404253.

    PMID: 39011492
  4. 4

    Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype.

    Ueda K, Yaoita M, Niihori T, et al.

    American journal of medical genetics. Part A 2017; (173(9)):2346-2352 doi:10.1002/ajmg.a.38337.

    PMID: 28650561
  5. 5

    RASopathies and cardiac manifestations.

    Hilal N, Chen Z, Chen MH, Choudhury S

    Frontiers in cardiovascular medicine 2023; (10()):1176828 doi:10.3389/fcvm.2023.1176828.

    PMID: 37529712
  6. 6

    Neurodevelopmental Aspects of RASopathies.

    Kim YE, Baek ST

    Molecules and cells 2019; (42(6)):441-447 doi:10.14348/molcells.2019.0037.

    PMID: 31250618
  7. 7

    SHP2 sails from physiology to pathology.

    Tajan M, de Rocca Serra A, Valet P, et al.

    European journal of medical genetics 2015; (58(10)):509-25.

    PMID: 26341048
  8. 8

    A Novel Homozygous Loss-of-Function Variant in SPRED2 Causes Autosomal Recessive Noonan-like Syndrome.

    Onore ME, Caiazza M, Farina A, et al.

    Genes 2023; (15(1)) doi:10.3390/genes15010032.

    PMID: 38254922
  9. 9

    Cardiovascular disease in Noonan syndrome.

    Pierpont ME, Digilio MC

    Current opinion in pediatrics 2018; (30(5)):601-608 doi:10.1097/MOP.0000000000000669.

    PMID: 30024444
  10. 10

    Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment.

    Linglart L, Gelb BD

    American journal of medical genetics. Part C, Seminars in medical genetics 2020; (184(1)):73-80 doi:10.1002/ajmg.c.31765.

    PMID: 32022400
  11. 11

    Cardiac features of Noonan syndrome in Japanese patients.

    Ichikawa Y, Kuroda H, Ikegawa T, et al.

    Cardiology in the young 2023; (33(4)):564-569 doi:10.1017/S104795112200124X.

    PMID: 35475426
  12. 12

    Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.

    Yaoita M, Niihori T, Mizuno S, et al.

    Human genetics 2016; (135(2)):209-22 doi:10.1007/s00439-015-1627-5.

    PMID: 26714497
  13. 13

    A Chinese family with Noonan syndrome caused by a heterozygous variant in LZTR1: a case report and literature review.

    Zhao X, Li Z, Wang L, et al.

    BMC endocrine disorders 2021; (21(1)):2 doi:10.1186/s12902-020-00666-6.

    PMID: 33407364
  14. 14

    Combined cardiac anomalies in Noonan syndrome: A case report.

    H S NS, S S, Patil R, et al.

    International journal of surgery case reports 2020; (72()):32-36 doi:10.1016/j.ijscr.2020.05.048.

    PMID: 32506025
  15. 15

    Management of failed Chiari decompression and intrasyringeal hemorrhage in Noonan syndrome: illustrative cases.

    Falls CJ, Page PS, Greeneway GP, et al.

    Journal of neurosurgery. Case lessons 2022; (3(4)).

    PMID: 36130568
  16. 16

    Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.

    Chinton J, Huckstadt V, Moresco A, et al.

    Archivos argentinos de pediatria 2019; (117(5)):330-337 doi:10.5546/aap.2019.eng.330.

    PMID: 31560489

This page provides educational information about the genetics and inheritance patterns of Noonan syndrome. Always consult a genetic counselor or healthcare provider to discuss your specific genetic test results and family risks.

Stay up to date

Get notified when new research about Noonan syndrome is published.

No spam. Unsubscribe anytime.